Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus and is sold as Torisel.

CAS：162635-04-3
中文别名：替西罗莫司;西罗莫司;
英文别名：CCL-779;Rapamycin (42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate];[14C]-Temsirolimus;TeMsiroliMus (CCI-779,Torisel);TeMsiroliMus (~);rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid;42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin;TeMsiroliMus (Torisel);Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;
分子式：C56H87NO16
分子量：1030.29
精确质量：1029.6
Psa：241.96
Logp：5.6603

UNII：624KN6GM2T

密度：1.2g/cm3
沸点：1048.4ºC at 760mmHg
熔点：99-101ºC
闪点：587.8ºC
折射率：1.553
蒸汽压：0mmHg at 25°C